Janney Montgomery lowered its rating on the stock to sell in the wake
Marketwatch - Specifically, Telcyta missed its primary endpoint to improve overall survival in an Assist-2 trial involving comparison to gefitinib as a third-line therapy for advanced non-small-cell lung cancer. It did the same in an Assist-1 trial evaluating
John Heath-Stubbs | British poet, 88
Philadelphia Inquirer - Heath-Stubbs, who slowly lost his eyesight and went completely blind in 1978, had been diagnosed with lung cancer earlier this year. Mr. Heath-Stubbs’ works included poetry, plays, criticism and translations, including The Rubaiyat of Omar Khayyam with
Short-term T-bill rates up
San Diego Union-Tribune - The San Diego drug development company said it would conduct clinical trials to establish that its drug, ANX-530, works the same as Navelbine, an anti-cancer agent approved to fight non-small-cell lung cancer. Adventrx will begin testing the drug in
Santa brings a gift to Wall Street
CNN Money - Elsewhere, shares of Telik ( Charts ) plunged 70 percent after the drugmaker said its experimental cancer drug failed to improve survival in patients with advanced lung cancer or ovarian cancer. With little news on the economic front, investors will be
Telik stock takes a 71% hit
Silicon Valley - In two of the tests, Telcyta failed to improve the survival rate of patients with ovarian and lung cancer. In a third study of Telcyta in combination with another drug, about one-fourth of the ovarian cancer patients “were discontinued prematurely
Passaic kids help cancer patient who helped them
El Nuevo Herald - The students held fundraisers to come up with money to help the uninsured Perez buy medicine he needs in his battle with lung cancer. They call him “The Angel of the Garden.” School staff learned that Perez, 54, can’t afford the anti-nausea medicine